期刊文献+

利拉鲁肽的药理及临床研究进展 被引量:13

Progress in pharmacological and clinical studies of liraglutide
原文传递
导出
摘要 利拉鲁肽是一种酰化胰高血糖素样肽-1(GLP-1)类似物,通过激活GLP-1受体,以葡萄糖依赖性刺激胰岛素分泌并抑制胰高血糖素分泌,临床用于2型糖尿病的二线治疗,可与其他口服降糖药联合使用,但不用于1型糖尿病的治疗。文中通过Medline对利拉鲁肽进行文献检索,并对其药理作用、药动学、临床研究、安全性和药物相互作用等进行综述。 Liraglutide is an analogue of acylated glucagon-like peptide-1(GLP-1).It can stimulate glucose-dependent insulin secretion and inhibit glucagon secretion by activating the GLP-1 receptor.Generally,liraglutide is used for second-line treatment of type 2 diabetes and can be combined with other oral hypoglycemic agents,but not used in the treatment of type 1 diabetes.A literature search was conducted using Medline with the key word liraglutide.The pharmacological effects,pharmackinetics,clinical research,safety and drug interactions of liraglutide were reviewed in this paper.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第23期2115-2119,2123,共6页 Chinese Journal of New Drugs
关键词 利拉鲁肽 胰高血糖素样肽-1类似物 2型糖尿病 liraglutide glucagon-like peptide-1 analog type 2 diabetes mellitus
  • 相关文献

参考文献19

  • 1National Institutes of Health. National diabetes statistics 2007 Wprevalence of diagnosed and undiagnosed diabetes in the United States, all ages, 2007 [ EB/OL]. [2009 - 08 - 14]. http ://diabetes. niddk. nih. gov/dm/pubs/statistics/#allages.
  • 2RUSSELL-JONES D. Molecular,pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J]. Mol Cell Endocrinol,2009,297 ( 12 ) : 137 - 140.
  • 3NAUCK MA, HEIMESAAT MM, BEHLE K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemie,stepped hypoglycemie clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002,87 (3) : 1239 - 1246.
  • 4ZINMAN B, GERICH J, BUSE JB,et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes(LEAD-4 Met + TZD ) [J]. Diabetes Care, 2009, 32 (7) : 1224 -1230.
  • 5BUSE JB, ROSENSTOCK J, SESTI G,et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial ( LEAD- 6)[J]. Lancet,2009,374(4): 39-47.
  • 6NAUCK M, MARRE M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits [ J ]. Postgrad Med, 2009,121(3): 5-15.
  • 7ASTRUP A, ROSSNER S, VAN GAAL L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind,placebo-controlled study [ J ]. Lancet, 2009, 374 ( 9701 ) : 1606 - 1616.
  • 8BOSE AK, MOCANU MM, CARR RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury[ J]. Diabetes,2005,54(1) :146 - 151.
  • 9MEECE J, FACA BS. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glueagon-like peptide-1 analog [J]. Pharmacotherapy, 2009,29(12) :33S-42S.
  • 10CROOM KF, MCCORMACK PL. Liraglutide: A Review of its use in type 2 diabetes mellitus[J]. Drugs, 2009, 69(14): 1985 - 2004.

同被引文献68

引证文献13

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部